Skip to main content

Rybelsus® 14 mg vs. Placebo in Adults with Moderate Renal Impairment (PIONEER 5 Study)

This video discusses the trial-design and outcomes of the PIONEER 5 study. PIONEER 5 was a 26-week, phase 3a, randomized, double-blind, multinational trial enrolling 324 adults with type 2 diabetes and moderate renal impairment.

Play
Pause
Skip
Volume
Chapters
Transcript
References
video_su
Fullscreen

Rybelsus® 14 mg vs. Placebo in Adults with Moderate Renal Impairment (PIONEER 5 Study)

Chapters
Transcript
References

Return to overview

Transcripts

Return to overview

References